Effect of Lianhua Qingwen granules/capsules on patients infected with the novel coronavirus: a multicenter, retrospective cohort study
Phase 2
Completed
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Asymptomatic infections and mild confirmed cases of the new coronavirus in accordance with the Diagnosis and Treatment Protocol of the Novel Coronavirus Pneumonia (Trial Version 9) after etiological testing;
2. Age = 18 years old, male or female.
Exclusion Criteria
1. The nucleic acid test is positive, and the patient is diagnosed as common type, severe type, or critical type;
2. Patients were nucleic acid-negative.
3. Patients were taking Chinese patent medicine such as Huashi Baidu Granules, Jinhua Qinggan Granules, Xuanfei Baidu Granules, and Chinese herbal decoctions such as Qinghua PiHui prescription, Fuzheng Huazhuo prescription, Puping Qinghua prescription at the same time.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method negative conversion rate of nucleic acid within 7 days;
- Secondary Outcome Measures
Name Time Method negative time of nucleic acid test;length of hospital stay;